End-of-day quote
Korea S.E.
06:00:00 2024-06-25 pm EDT
|
5-day change
|
1st Jan Change
|
14,890
KRW
|
+2.06%
|
|
+0.95%
|
+4.13%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
418,055
|
311,744
|
458,326
|
313,809
|
230,539
|
196,819
|
Enterprise Value (EV)
1 |
543,979
|
496,560
|
658,619
|
536,764
|
488,981
|
476,774
|
P/E ratio
|
52.1
x
|
8.9
x
|
17
x
|
95.4
x
|
21.6
x
|
-6.84
x
|
Yield
|
1.47%
|
1.21%
|
0.9%
|
1.54%
|
2.39%
|
2.1%
|
Capitalization / Revenue
|
0.94
x
|
0.66
x
|
0.91
x
|
0.61
x
|
0.42
x
|
0.38
x
|
EV / Revenue
|
1.22
x
|
1.05
x
|
1.31
x
|
1.04
x
|
0.9
x
|
0.91
x
|
EV / EBITDA
|
13
x
|
10.1
x
|
13.2
x
|
10.9
x
|
9.73
x
|
13.6
x
|
EV / FCF
|
27.3
x
|
-22.8
x
|
-456
x
|
73.4
x
|
-14.4
x
|
177
x
|
FCF Yield
|
3.66%
|
-4.39%
|
-0.22%
|
1.36%
|
-6.94%
|
0.56%
|
Price to Book
|
1.36
x
|
0.91
x
|
1.2
x
|
0.82
x
|
0.61
x
|
0.58
x
|
Nbr of stocks (in thousands)
|
13,617
|
13,764
|
13,764
|
13,764
|
13,764
|
13,764
|
Reference price
2 |
30,700
|
22,650
|
33,300
|
22,800
|
16,750
|
14,300
|
Announcement Date
|
3/15/19
|
3/3/20
|
3/18/21
|
3/16/22
|
3/9/23
|
3/14/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
446,731
|
473,000
|
503,612
|
517,641
|
543,759
|
522,741
|
EBITDA
1 |
41,985
|
49,032
|
49,830
|
49,374
|
50,255
|
35,067
|
EBIT
1 |
22,075
|
27,452
|
28,376
|
28,006
|
28,496
|
12,579
|
Operating Margin
|
4.94%
|
5.8%
|
5.63%
|
5.41%
|
5.24%
|
2.41%
|
Earnings before Tax (EBT)
1 |
9,344
|
48,470
|
42,128
|
4,768
|
7,316
|
-33,508
|
Net income
1 |
7,990
|
34,929
|
26,960
|
3,295
|
10,684
|
-28,797
|
Net margin
|
1.79%
|
7.38%
|
5.35%
|
0.64%
|
1.96%
|
-5.51%
|
EPS
2 |
589.0
|
2,544
|
1,958
|
239.0
|
775.9
|
-2,091
|
Free Cash Flow
1 |
19,933
|
-21,809
|
-1,444
|
7,308
|
-33,947
|
2,692
|
FCF margin
|
4.46%
|
-4.61%
|
-0.29%
|
1.41%
|
-6.24%
|
0.51%
|
FCF Conversion (EBITDA)
|
47.48%
|
-
|
-
|
14.8%
|
-
|
7.68%
|
FCF Conversion (Net income)
|
249.49%
|
-
|
-
|
221.81%
|
-
|
-
|
Dividend per Share
2 |
450.0
|
275.0
|
300.0
|
350.0
|
400.0
|
300.0
|
Announcement Date
|
3/15/19
|
3/3/20
|
3/18/21
|
3/16/22
|
3/9/23
|
3/14/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
125,924
|
184,816
|
200,293
|
222,956
|
258,442
|
279,956
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
2.999
x
|
3.769
x
|
4.02
x
|
4.516
x
|
5.143
x
|
7.983
x
|
Free Cash Flow
1 |
19,933
|
-21,809
|
-1,444
|
7,308
|
-33,947
|
2,692
|
ROE (net income / shareholders' equity)
|
2.34%
|
10.3%
|
7.43%
|
0.86%
|
2.77%
|
-8.01%
|
ROA (Net income/ Total Assets)
|
2.14%
|
2.45%
|
2.26%
|
2.11%
|
2.08%
|
0.95%
|
Assets
1 |
374,094
|
1,426,361
|
1,191,482
|
156,286
|
513,681
|
-3,043,162
|
Book Value Per Share
2 |
22,573
|
24,816
|
27,703
|
27,900
|
27,596
|
24,611
|
Cash Flow per Share
2 |
2,387
|
1,311
|
1,722
|
2,212
|
2,677
|
1,203
|
Capex
1 |
15,767
|
22,032
|
20,438
|
43,018
|
36,205
|
19,208
|
Capex / Sales
|
3.53%
|
4.66%
|
4.06%
|
8.31%
|
6.66%
|
3.67%
|
Announcement Date
|
3/15/19
|
3/3/20
|
3/18/21
|
3/16/22
|
3/9/23
|
3/14/24
|
|
1st Jan change
|
Capi.
|
---|
| +4.13% | 144M | | +54.61% | 815B | | +44.25% | 654B | | -6.33% | 354B | | +20.62% | 337B | | +10.44% | 302B | | +18.45% | 247B | | +2.09% | 229B | | +13.03% | 219B | | +8.61% | 171B |
Other Pharmaceuticals
|